Skip to main content

Purification and Functional Characterization of Factor I

  • Protocol
  • First Online:
The Complement System

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1100))

Abstract

Factor I (FI) is a soluble, 88 kDa glycoprotein present in plasma at a concentration of approximately 35 mg/L. FI inhibits all complement pathways as it degrades activated C4b and C3b when these are bound to a cofactor such as C4b-binding protein or factor H. Here, we describe a method for purification of FI from human plasma, which is based on affinity chromatography followed by anion exchange chromatography. We also describe a functional assay, in which activity of FI can be assessed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Morris KM, Aden DP, Knowles BB et al (1982) Complement biosynthesis by the human hepatoma-derived cell line HepG2. J Clin Invest 70:906–913

    Article  PubMed  CAS  Google Scholar 

  2. Goldberger G, Arnaout MA, Aden D et al (1984) Biosynthesis and postsynthetic processing of human C3b/C4b inactivator (factor I) in three hepatoma cell lines. J Biol Chem 259:6492–6497

    PubMed  CAS  Google Scholar 

  3. Nilsson SC, Karpman D, Vaziri-Sani F et al (2007) A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 44:1835–1844

    Article  PubMed  CAS  Google Scholar 

  4. Ullman CG, Chamberlain D, Ansari A et al (1998) Human complement factor I: its expression by insect cells and its biochemical and structural characterisation. Mol Immunol 35:503–512

    Article  PubMed  CAS  Google Scholar 

  5. Chamberlain D, Ullman CG, Perkins SJ (1998) Possible arrangement of the five domains in human complement factor I as determined by a combination of X-ray and neutron scattering and homology modeling. Biochemistry 37:13918–13929

    Article  PubMed  CAS  Google Scholar 

  6. Tsiftsoglou SA, Willis AC, Li P et al (2005) The catalytically active serine protease domain of human complement factor I. Biochemistry 44:6239–6249

    Article  PubMed  CAS  Google Scholar 

  7. Roversi P, Johnson S, Caesar JJ et al (2011) Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc Natl Acad Sci USA 108:12839–12844

    Article  PubMed  CAS  Google Scholar 

  8. Tsiftsoglou SA, Sim RB (2004) Human complement factor I does not require cofactors for cleavage of synthetic substrates. J Immunol 173:367–375

    PubMed  CAS  Google Scholar 

  9. Amadei N, Baracho GV, Nudelman V et al (2001) Inherited complete factor I deficiency associated with systemic lupus erythematosus, higher susceptibility to infection and low levels of factor H. Scand J Immunol 53:615–621

    Article  PubMed  CAS  Google Scholar 

  10. Nilsson SC, Trouw LA, Renault N et al (2009) Genetic, molecular and functional analyses of complement factor I deficiency. Eur J Immunol 39:310–323

    Article  PubMed  CAS  Google Scholar 

  11. Sadallah S, Gudat F, Laissue JA et al (1999) Glomerulonephritis in a patient with complement factor I deficiency. Am J Kidney Dis 33:1153–1157

    Article  PubMed  CAS  Google Scholar 

  12. Bienaime F, Dragon-Durey MA, Regnier CH et al (2010) Mutations in components of complement influence the outcome of Factor I-associated atypical hemolytic uremic syndrome. Kidney Int 77:339–349

    Article  PubMed  CAS  Google Scholar 

  13. Esparza-Gordillo J, Jorge EG, Garrido CA et al (2006) Insights into hemolytic uremic syndrome: segregation of three independent predisposition factors in a large, multiple affected pedigree. Mol Immunol 43:1769–1775

    Article  PubMed  CAS  Google Scholar 

  14. Kavanagh D, Kemp EJ, Mayland E et al (2005) Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 16:2150–2155

    Article  PubMed  CAS  Google Scholar 

  15. Nilsson SC, Kalchishkova N, Trouw LA et al (2010) Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 40:172–185

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media, New York

About this protocol

Cite this protocol

Nilsson, S.C., Blom, A.M. (2014). Purification and Functional Characterization of Factor I. In: Gadjeva, M. (eds) The Complement System. Methods in Molecular Biology, vol 1100. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-62703-724-2_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-62703-724-2_15

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-62703-723-5

  • Online ISBN: 978-1-62703-724-2

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics